Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Valeant Pharmaceuticals International Inc (NYSE:VRX)

15.08
Delayed Data
As of Dec 07
 -0.55 / -3.52%
Today’s Change
13.77
Today|||52-Week Range
119.87
-85.16%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$5.3B

Company Description

Valeant Pharmaceuticals International, Inc. is a pharmaceutical company which engages in developing, manufacturing, and marketing pharmaceutical products in the areas of dermatology, eye health, neurology, and generics. It operates through the Developed Markets and Emerging Markets. The Developed Markets segment offers over-the-counter and medical products as well as alliance and contract service revenues, in the areas of dermatology and podiatry, neurology, gastrointestinal disorders, eye health, oncology and urology, dentistry, aesthetics, and women's health. The Emerging Markets consists of branded generic pharmaceutical and branded pharmaceuticals; over-the-counter and medical device products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Contact Information

Valeant Pharmaceuticals International, Inc.
2150, St. Elzéar boulevard Ouest
Laval Quă©bec H7L 4A8
P:(514) 744-6792
Investor Relations:

Employees

Shareholders

Individual stakeholders7.19%
Other institutional48.30%
Mutual fund holders18.85%

Top Executives

Joseph C. PapaChairman & Chief Executive Officer
Paul S. HerendeenChief Financial Officer & Executive VP-Finance
Tage RamakrishnaChief Medical Officer, President-R&D
Ari KellenExecutive Vice President
Anne C. WhitakerExecutive Vice President